The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Feb 10

PMID 38339392

Authors

Osnat Elyashiv

Natalie Aleohin

Zohar Migdan

Sophia Leytes

Ofri Peled

Ori Tal

Tally Levy

Affiliations

Soon will be listed here.

Abstract

Objective: The goal of this study was to evaluate response to treatment and survival in epithelial ovarian cancer patients with acquired secondary platinum resistance (SPR) compared to patients with primary platinum resistance (PPR).

Methods: Patients were categorized as PPR (patients with disease recurrence occurring during or <6 months after completing first-line platinum-based chemotherapy) and SPR (patients with previously platinum-sensitive disease that developed platinum resistance on subsequent treatments). Clinico-pathological variables and treatment outcomes were compared.

Results: Of the 118 patients included in this study, 60 had PPR and 58 developed SPR. The SPR women had a significantly higher rate of optimal debulking during their upfront and interval operations, significantly lower CA-125 levels during their primary treatment, and a significantly higher complete and partial response rate to primary chemotherapy. Once platinum resistance appeared, no significant difference in survival was observed between the two groups. The median PFS was 2 months in the PPR group and 0.83 months in the SPR group ( = 0.085). Also, no significant difference was found in post-platinum-resistant relapse survival, with a median of 17.63 months in the PPR and 20.26 months in the SPR group ( = 0.515).

Conclusions: Platinum resistance is an important prognostic factor in women with EOC. Patients with SPR acquire the same poor treatment outcome as with PPR. There is a great need for future research efforts to discover novel strategies and biological treatments to reverse resistance and improve survival.

Citing Articles

Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum‑resistant recurrent ovarian cancer: A retrospective study.

Li H, Xiao J, Tian M Oncol Lett. 2024; 29(1):44.

PMID: 39554535 PMC: 11565270. DOI: 10.3892/ol.2024.14790.

References

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

Cecere S, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G . Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. Gynecol Oncol. 2019; 156(1):38-44. DOI: 10.1016/j.ygyno.2019.10.023. View

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T . Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. J Cancer Res Clin Oncol. 2008; 135(4):551-7. DOI: 10.1007/s00432-008-0488-x. View

Davis A, Tinker A, Friedlander M . "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. Gynecol Oncol. 2014; 133(3):624-31. DOI: 10.1016/j.ygyno.2014.02.038. View

Konstantinopoulos P, Waggoner S, Vidal G, Mita M, Moroney J, Holloway R . Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019; 5(8):1141-1149. PMC: 6567832. DOI: 10.1001/jamaoncol.2019.1048. View

10.

Sakai W, Swisher E, Karlan B, Agarwal M, Higgins J, Friedman C . Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451(7182):1116-20. PMC: 2577037. DOI: 10.1038/nature06633. View

11.

Pujade-Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A . Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9):1274-1284. DOI: 10.1016/S1470-2045(17)30469-2. View

12.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

13.

Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T . Clinical features of long-term survivors of recurrent epithelial ovarian cancer. Int J Clin Oncol. 2014; 20(1):143-9. DOI: 10.1007/s10147-014-0687-1. View

14.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

15.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

16.

Frenel J, Kim J, Aryal N, Asher R, Berton D, Vidal L . Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. 2022; 33(10):1021-1028. DOI: 10.1016/j.annonc.2022.06.011. View

17.

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

18.

Markman M, Bookman M . Second-line treatment of ovarian cancer. Oncologist. 2000; 5(1):26-35. DOI: 10.1634/theoncologist.5-1-26. View

19.

Hanker L, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E . The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012; 23(10):2605-2612. DOI: 10.1093/annonc/mds203. View

20.

Monk B, Parkinson C, Lim M, OMalley D, Oaknin A, Wilson M . A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022; 40(34):3952-3964. PMC: 9746782. DOI: 10.1200/JCO.22.01003. View